
Luca Piccoli

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2914944/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Poor neutralization and rapid decay of antibodies to SARS-CoV-2 variants in vaccinated dialysis patients. PLoS ONE, 2022, 17, e0263328.	1.1	21
2	Broadly neutralizing antibodies overcome SARS-CoV-2 Omicron antigenic shift. Nature, 2022, 602, 664-670.	13.7	917
3	Structural basis of malaria RIFIN binding by LILRB1-containing antibodies. Nature, 2021, 592, 639-643.	13.7	8
4	Circulating SARS-CoV-2 spike N439K variants maintain fitness while evading antibody-mediated immunity. Cell, 2021, 184, 1171-1187.e20.	13.5	541
5	Sensitivity of SARS-CoV-2 B.1.1.7 to mRNA vaccine-elicited antibodies. Nature, 2021, 593, 136-141.	13.7	648
6	Recurrent emergence of SARS-CoV-2 spike deletion H69/V70 and its role in the Alpha variant B.1.1.7. Cell Reports, 2021, 35, 109292.	2.9	375
7	Machine learning analyses of antibody somatic mutations predict immunoglobulin light chain toxicity. Nature Communications, 2021, 12, 3532.	5.8	23
8	SARS-CoV-2 immune evasion by the B.1.427/B.1.429 variant of concern. Science, 2021, 373, 648-654.	6.0	385
9	Structural basis of LAIR1 targeting by polymorphic Plasmodium RIFINs. Nature Communications, 2021, 12, 4226.	5.8	1
10	SARS-CoV-2 RBD antibodies that maximize breadth and resistance to escape. Nature, 2021, 597, 97-102.	13.7	385
11	SARS-CoV-2 B.1.617.2 Delta variant replication and immune evasion. Nature, 2021, 599, 114-119.	13.7	1,041
12	Broad betacoronavirus neutralization by a stem helix–specific human antibody. Science, 2021, 373, 1109-1116.	6.0	262
13	Exceptionally potent human monoclonal antibodies are effective for prophylaxis and treatment of tetanus in mice. Journal of Clinical Investigation, 2021, 131, .	3.9	8
14	Mapping Neutralizing and Immunodominant Sites on the SARS-CoV-2 Spike Receptor-Binding Domain by Structure-Guided High-Resolution Serology. Cell, 2020, 183, 1024-1042.e21.	13.5	1,195
15	European Immunogenicity Platform 11th Open Scientific Symposium on immunogenicity of biopharmaceuticals. Bioanalysis, 2020, 12, 1043-1048.	0.6	1
16	A single T cell epitope drives the neutralizing anti-drug antibody response to natalizumab in multiple sclerosis patients. Nature Medicine, 2019, 25, 1402-1407.	15.2	50
17	Detection and kinetics of persistent neutralizing anti-interferon-beta antibodies in patients with multiple sclerosis. Results from the ABIRISK prospective cohort study. Journal of Neuroimmunology, 2019, 326, 19-27.	1.1	22
18	A public antibody lineage that potently inhibits malaria infection through dual binding to the circumsporozoite protein. Nature Medicine, 2018, 24, 401-407.	15.2	183

LUCA PICCOLI

#	Article	IF	CITATIONS
19	Rituximab in multiple sclerosis: Frequency and clinical relevance of anti-drug antibodies. Multiple Sclerosis Journal, 2018, 24, 1224-1233.	1.4	86
20	Public antibodies to malaria antigens generated by two LAIR1 insertion modalities. Nature, 2017, 548, 597-601.	13.7	91
21	A LAIR1 insertion generates broadly reactive antibodies against malaria variant antigens. Nature, 2016, 529, 105-109.	13.7	140
22	Broadly neutralizing antibodies overcome SARS-CoV-2 Omicron antigenic shift. Nature, 0, , .	13.7	101